Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database
Diogo Mota, Tiago Azenha Rama, Mílton Severo, André Moreira
Topics & Concepts
MedicinePharmacovigilanceHumanitiesPhilosophyPharmacologyAdverse effectDrug-Induced Adverse ReactionsAsthma and respiratory diseasesMonoclonal and Polyclonal Antibodies Research